Hostname: page-component-76d6cb85b7-2r2wp Total loading time: 0 Render date: 2026-07-27T19:32:10.240Z Has data issue: false hasContentIssue false

Randomised, double-blinded, placebo-controlled, clinical trial of ozone therapy as treatment of sudden sensorineural hearing loss

Published online by Cambridge University Press:  17 October 2008

A Ragab*
Affiliation:
Department of ORL Head and Neck Surgery, Menofia University Hospital, Egypt
E Shreef
Affiliation:
Department of ORL Head and Neck Surgery, Menofia University Hospital, Egypt
E Behiry
Affiliation:
Department of ORL Head and Neck Surgery, Menofia University Hospital, Egypt
S Zalat
Affiliation:
Department of Anesthesiology, Menofia University Hospital, Egypt
M Noaman
Affiliation:
Department of ORL Head and Neck Surgery, Menofia University Hospital, Egypt
*
Address for correspondence: Professor Ahmed Ragab, Lecturer and Consultant, ORL Head and Neck Surgery Department, Menofia University Hospital, 73 Sayed St, Tanta, Egypt. Fax: 00 20 40 3315000 E-mail: ahmedragab2000@hotmail.com

Abstract

Objective:

To investigate the safety and efficacy of ozone therapy in adult patients with sudden sensorineural hearing loss.

Design:

Prospective, randomised, double-blinded, placebo-controlled, parallel group, clinical trial.

Subjects:

Forty-five adult patients presented with sudden sensorineural hearing loss, and were randomly allocated to receive either placebo (15 patients) or ozone therapy (auto-haemotherapy; 30 patients). For the latter treatment, 100 ml of the patient's blood was treated immediately with a 1:1 volume, gaseous mixture of oxygen and ozone (from an ozone generator) and re-injected into the patient by intravenous infusion. Treatments were administered twice weekly for 10 sessions. The following data were recorded: pre- and post-treatment mean hearing gains; air and bone pure tone averages; speech reception thresholds; speech discrimination scores; and subjective recovery rates.

Results:

Significant recovery was observed in 23 patients (77 per cent) receiving ozone treatment, compared with six (40 per cent) patients receiving placebo (p < 0.05). Mean hearing gains, pure tone averages, speech reception thresholds and subjective recovery rates were significantly better in ozone-treated patients compared with placebo-treated patients (p < 0.05).

Conclusion:

Ozone therapy is a significant modality for treatment of sudden sensorineural hearing loss; no complications were observed.

Information

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable